Krystal Biotech is trading 5.1% down at $334.00 in after-hours as it gives back gains from its recent rally following its addition to the S&P MidCap 400.
- The stock climbed 4.1% during the regular session amid a bullish biotech tape and risk-on sentiment.
- There is no fresh company-specific news or earnings release tied to the post-close drop, suggesting normal profit-taking and repricing in thinner after-hours trading.